The role of bioidentical hormone replacement therapy in anti-aging medicine: a review of the literature.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
revised:
05
07
2019
received:
27
04
2019
accepted:
10
09
2019
pubmed:
13
10
2019
medline:
13
10
2019
entrez:
13
10
2019
Statut:
ppublish
Résumé
The changes in skin and overall appearance that occur with increasing age can be partly attributed to declining hormone levels. While hormonal deficiencies are most commonly associated with postmenopausal females, males are also subject to age-related testosterone decline and may benefit from replacement of deficient hormones. However, great disparities exist between the recommendations of scientific societies and actual use of hormone supplements in aging patients. The purpose of this literature review is to discuss the role of hormones in the aging process of the skin, explain the safety profile of hormone replacement therapy, specifically discussing the superiority of bioidentical hormones, and highlight the benefits of hormone replacement in anti-aging of the skin. In summary, this literature review suggests that hormone replacement with bioidentical hormones is a safe and effective way to prevent skin aging.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-29Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 The International Society of Dermatology.
Références
Lephart ED. Skin aging and oxidative stress: equol's anti-aging effects via biochemical and molecular mechanisms. Ageing Res Rev 2016; 2016: 36-54.
Lephart ED. A review of the role of estrogen in dermal aging and facial attractiveness in women. J Cosmet Dermatol 2018; 17: 282-288.
Quan C, Cho MK, Perry D, et al. Age-associated reduction of cell spreading induces mitochondrial DNA common deletion by oxidative stress in human skin dermal fibroblasts: implication for human skin connective tissue aging. J Biomed Sci 2015; 22: 62.
Qin Z, Voorhees JJ, Fisher GJ, et al. Age-associated reduction of cellular spreading/mechanical force up-regulates matrix metalloproteinase-1 expression and collagen fibril fragmentation via c-Jun/AP-1 in human dermal fibroblasts. Aging Cell 2014; 13: 1028-1037.
Farage MA, Miller KW, Elsner P, et al. Structural characteristics of the aging skin: a review. Cutan Ocul Toxicol 2007; 26: 343-357.
Dhaked D. Aging face ppt. [online] Slideshare.net. 2014. Available at: https://www.slideshare.net/daulatramdhaked/aging-face-ppt (Accessed 23 March 2019).
Thornton MJ. Estrogens and aging skin. Dermatoendocrinol 2013; 5: 264-270.
Archer DF. Postmenopausal skin and estrogen. Gynecol Endocrinol 2012; 28: 2-6.
Verdier-Sevrain S, Bonte G, Gilchrest B. Biology of estrogen in skin: implications for skin aging. Exp Dermatol 2006; 15: 83-94.
Verdier-Sevrain S. Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators. Climacteric 2007; 10: 289-97.
Gopaul R, Knaggs H, Lephart ED. Biochemical investigation and gene analysis of equol: a plant and soy-derived isoflavonoid with anti-aging and anti-oxidant properties with potential human skin applications. BioFactors 2012; 38: 44-52.
Wildt L, Petermann T. Oestrogen and age estimations of perimenopausal women. Lancet 1999; 354: 224.
Sator PG, Schmidt JB, Sator MO, et al. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001; 39: 43-55.
Brincat M, Moniz CJ, Studd JW, et al. Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985; 92: 256-259.
Savvas M, Bishop J, Laurent G, et al. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. BJOG 1993; 100: 154-156.
Nouveau S, Bastien P, Baldo F, et al. Effects of topical DHEA on aging skin: a pilot study. Maturitas 2008; 59: 174-181.
Rudman D, Feller AG, Cohn L, et al. Effects of human growth hormone on body composition in elderly men. Horm Res 1991; 36(Suppl. 1): 73-81.
Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. New Engl J Med 1990; 323: 1-6.
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353-1368.
Chester RC, Kling JM, Manson JE. What the Women's Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol 2018; 41: 248-253.
Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos early estrogen prevention study. Climacteric 2005; 8: 3-12.
Hodis HN, Mack WJ, Shoupe D, et al. Testing the menopausal hormone therapy timing hypothesis: the early versus late intervention trial with estradiol. Circulat 2014; 130(Suppl_2): A13283.
Karas R, Clarkson T. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI (timing is everything). Menopausal Med 2003; 10: 8-12.
Goodman N, Goldzieher J, Ayala C. Critique of the report from the writing group of the WHI. Menopausal Med 2003; 10: 1-4.
Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy after breast cancer: meta-analysis. J Fam Pract 2002; 51: 1056-1064.
Kotsopoulos J, Gronwald J, Karlan BY, et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol 2018; 4: 1059-1065.
Zeng Z, Jiang X, Li X, et al. Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls. PLoS ONE 2018; 13: e0197064.
Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012; 15: 11-17.
Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. Altern Med Rev 2006; 11: 208-223.
L’Hermite M, Simoncini T, Fuller S, et al. Could transdermal estradiol+ progesterone be a safer postmenopausal HRT? A review. Maturitas 2008; 60: 185-201.
Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114: 448-454.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103-11.
Morley JE. Testosterone replacement and the physiologic aspects of aging in men. Mayo Clin Proc 2000; 75(Suppl): S83-S87.
Pierorazio PM, Ferrucci L, Kettermann A, et al. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 2010; 105: 824-829.
Travis RC, Key TJ, Allen NE, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European prospective investigation into cancer and nutrition. Int J Cancer 2007; 121: 1331-1338.
Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-183.
Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007; 34: 555-563.
Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003; 24: 313-340.
Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) Study in Sweden. J Am Coll Cardiol 2011; 58: 1674-1681.
Hyde Z, Norman PE, Flicker L, et al. Elevated LH predicts ischaemic heart disease events in older men: the health in men study. Eur J Endocrinol 2011; 164: 569-577.
Yeap BB, Hyde Z, Norman PE, et al. Associations of total testosterone, sex hormone-binding globulin, calculated free testosterone, and luteinizing hormone with prevalence of abdominal aortic aneurysm in older men. J Clin Endocrinol Metab 2010; 95: 1123-1130.
Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007; 19: 176-182.
English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-894.
Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353-2359.
Cole AP, Hanske J, Jiang W, et al. Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU Int 2018; 121: 811-818.
English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo controlled study. Circulation 2000; 102: 1906-1911.
Botteri E, Støer NC, Sakshaug S, et al. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer 2017; 141: 1763-1770.
Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone replacement therapy. Available at: https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormone-therapy#H1345819194 (Accessed 06 April 2019).
Sator PG, Sator MO, Schmidt JB, et al. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. Climacteric 2007; 10: 320-34.
Phillips TJ, Demircay Z, Sahu M. Hormonal effects on skin aging. Clin Geriatr Med 2001; 17: 661-672.
Sauerbronn AV, Fonseca AM, Bagnoli VR, et al. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. Int J Gynecol Obstet 2000; 68: 35-41.
Varila E, Rantala I, Oikarinen A, et al. The effect of topical estradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995; 102: 985-989.
Maheux R, Naud F, Rioux M, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170: 642-649.
Owen CM, Pal L, Mumford SL, et al. Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. Fertil Steril 2016; 106: 1170-1175.
Phillips TJ, Symons J, Menon S; et al. Does hormone therapy improve age-related skin changes in postmenopausal women?: A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. J Am Acad Dermatol 2008; 59: 397-404.
Punnonen R, Vaajalahti P, Teisala K. Local oestriol treatment improves the structure of elastic fibers in the skin of postmenopausal women. Annal Chir Gynaecol Suppl 1987; 202: 39-41.
Callens A, Valliant L, Lecomte P, et al. Does hormonal skin aging exist? A study of the infl uence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatol 1996; 193: 289-294.
Draelos ZD. A double-blind randomized pilot study evaluating the safety and efficacy of topical MEP in the facial appearance improvement of estrogen deficient females. J Drugs Dermatol 2018; 17: 1186-1189.
Creidi P, Faivre B, Agache P, et al. Effect of a conjugated oestrogen (Premarin®) cream on ageing facial skin. A comparative study with a placebo cream. Maturitas 1994; 19: 211-223.
Dunn LB, Damesyn M, Moore AA, et al. Does estrogen prevent skin aging?: Results from the first National Health and Nutrition Examination Survey (NHANES I). Arch Dermatol 1997; 133: 339-342.
Rzepecki AK, Murase JE, Juran R, et al. Estrogen-deficient skin: the role of topical therapy. Int J Womens Dermatol 2019; 5: 85-90.
Brincat M, Moniz CF, Studd JW, et al. Sex hormones and skin collagen content in postmenopausal women. Br Med J (Clin Res Ed) 1983; 287: 1337-1338.
Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000; 97: 4279-4284.
Shin MH, Rhie GE, Park CH, et al. Modulation of collagen metabolism by the topical application of dehydroepiandrosterone to human skin. J Invest Dermatol 2005; 124: 315-323.
Calvo E, Luu-The V, Morissette J, et al. Pangenomic changes induced by DHEA in the skin of postmenopausal women. J Steroid Biochem Mol Biol 2008; 112: 186-193.
El-Alfy M, Deloche C, Azzi L, et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? Br J Dermatol 2010; 163: 968-976.
Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49: 421-432.